Allogene Therapeutics Eulerpool Ziņas

Allogene Therapeutics Eulerpool News

Allogene Therapeutics Akciju Ziņas

Allogene Therapeutics tiek uzmanīgi vēroti no žurnālistu un investoru puses visā pasaulē. Jaunākās Allogene Therapeutics ziņas mēs apkopojam šeit.

• 1. jūlijs ·

  Yahoo
  Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
• 27. jūnijs ·

  Yahoo
  With 56% institutional ownership, Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst the big guns
• 27. jūnijs ·

  Yahoo
  Allogene Therapeutics, Inc. (ALLO): Are Analysts Bullish About the Potential of This Small-Cap Stock?
• 20. jūnijs ·

  Yahoo
  Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
• 20. jūnijs ·

  Thefly.com
  Allogene Therapeutics initiates Phase 2 cema-cel trial
• 17. jūnijs ·

  TipRanks
  Piper Sandler Remains a Buy on Allogene Therapeutics (ALLO)
• 13. jūnijs ·

  Thefly.com
  Allogene Therapeutics participates in a conference call with JPMorgan
• 12. jūnijs ·

  Yahoo
  Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?
• 12. jūnijs ·

  SeekingAlpha
  Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products
• 10. jūnijs ·

  TipRanks
  Allogene Therapeutics Enhances Leadership and Affirms Shareholder Decisions